Inozyme Pharma, Inc. (INZY)

NASDAQ: INZY · IEX Real-Time Price · USD
7.35
-0.04 (-0.54%)
Mar 28, 2024, 12:07 PM EDT - Market open

Total Valuation

Inozyme Pharma has a market cap or net worth of $453.10 million. The enterprise value is $310.79 million.

Market Cap 453.10M
Enterprise Value 310.79M

Important Dates

The last earnings date was Tuesday, March 12, 2024, before market open.

Earnings Date Mar 12, 2024
Ex-Dividend Date n/a

Share Statistics

Inozyme Pharma has 61.77 million shares outstanding. The number of shares has increased by 37.27% in one year.

Shares Outstanding 61.77M
Shares Change (YoY) +37.27%
Shares Change (QoQ) +9.01%
Owned by Insiders (%) 0.65%
Owned by Institutions (%) 92.77%
Float 34.16M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 3.23
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 13.36, with a Debt / Equity ratio of 0.33.

Current Ratio 13.36
Quick Ratio n/a
Debt / Equity 0.33
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -20.35

Financial Efficiency

Return on equity (ROE) is -55.90% and return on invested capital (ROIC) is -40.44%.

Return on Equity (ROE) -55.90%
Return on Assets (ROA) -40.70%
Return on Capital (ROIC) -40.44%
Revenue Per Employee n/a
Profits Per Employee -$1.21M
Employee Count 59
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +99.73% in the last 52 weeks. The beta is 1.34, so Inozyme Pharma's price volatility has been higher than the market average.

Beta (1Y) 1.34
52-Week Price Change +99.73%
50-Day Moving Average 5.67
200-Day Moving Average 4.76
Relative Strength Index (RSI) 70.62
Average Volume (30 Days) 531,244

Short Selling Information

The latest short interest is 2.38 million, so 3.86% of the outstanding shares have been sold short.

Short Interest 2.38M
Short Previous Month 2.32M
Short % of Shares Out 3.86%
Short % of Float 6.98%
Short Ratio (days to cover) 4.55

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -75.65M
Pretax Income -71.17M
Net Income -71.17M
EBITDA -66.51M
EBIT -67.84M
Earnings Per Share (EPS) -$1.37
Full Income Statement

Balance Sheet

The company has $188.90 million in cash and $46.59 million in debt, giving a net cash position of $142.31 million or $2.30 per share.

Cash & Cash Equivalents 188.90M
Total Debt 46.59M
Net Cash 142.31M
Net Cash Per Share $2.30
Equity / Book Value 140.48M
Book Value Per Share 2.27
Working Capital 181.56M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$70.68 million and capital expenditures -$298,000, giving a free cash flow of -$70.97 million.

Operating Cash Flow -70.68M
Capital Expenditures -298,000
Free Cash Flow -70.97M
FCF Per Share -$1.37
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Inozyme Pharma does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -37.27%
Shareholder Yield -37.27%
Earnings Yield -15.71%
FCF Yield -15.66%

Analyst Forecast

The average price target for Inozyme Pharma is $18.00, which is 144.90% higher than the current price. The consensus rating is "Strong Buy".

Price Target $18.00
Price Target Difference 144.90%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

Altman Z-Score n/a
Piotroski F-Score 2